New Risk • May 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (52% average weekly change). Negative equity (-€21m). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (488% increase in shares outstanding). Market cap is less than US$10m (€13.5k market cap, or US$15.7k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). 공시 • Aug 14
Europlasma S.A., Annual General Meeting, Sep 23, 2025 Europlasma S.A., Annual General Meeting, Sep 23, 2025. Location: cite de la photonique, batiment sirah, 3 5 allee des lumieres, pessac France New Risk • Jun 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €8.38m (US$9.62m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€12m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-€11m). Earnings have declined by 9.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 645x increase in shares outstanding). Market cap is less than US$10m (€8.38m market cap, or US$9.62m). Reported Earnings • Jun 17
Full year 2024 earnings released: €0.015 loss per share (vs €1,048 loss in FY 2023) Full year 2024 results: €0.015 loss per share. Revenue: €41.9m (up 171% from FY 2023). Net loss: €15.3m (loss widened 3.7% from FY 2023). New Risk • May 18
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Shareholders have been substantially diluted in the past year (over 1321x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€9.82m market cap, or US$10.9m). 공시 • Apr 30
Europlasma S.A. (ENXTPA:ALEUP) acquired Fonderies de Bretagne. Europlasma S.A. (ENXTPA:ALEUP) acquired Fonderies de Bretagne on April 28, 2025. The Commercial Court of Rennes has approved the deal.
Europlasma S.A. (ENXTPA:ALEUP) completed the acquisition of Fonderies de Bretagne on April 28, 2025. 공시 • Jul 23
Europlasma S.A., Annual General Meeting, Sep 24, 2024 Europlasma S.A., Annual General Meeting, Sep 24, 2024. Location: cite de la photonique batiment sirah, 3 5 allee des lumieres, pessac France New Risk • May 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (85% average weekly change). Negative equity (-€362k). Shareholders have been substantially diluted in the past year (over 2086x increase in shares outstanding). Market cap is less than US$10m (€2.97m market cap, or US$3.21m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Reported Earnings • May 27
Full year 2023 earnings released: €0.21 loss per share (vs €26.32 loss in FY 2022) Full year 2023 results: €0.21 loss per share (improved from €26.32 loss in FY 2022). Revenue: €17.4m (up 17% from FY 2022). Net loss: €14.7m (loss narrowed 7.4% from FY 2022). New Risk • May 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (82% average weekly change). Negative equity (-€362k). Shareholders have been substantially diluted in the past year (over 328x increase in shares outstanding). Market cap is less than US$10m (€2.29m market cap, or US$2.47m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). New Risk • Oct 29
New major risk - Negative shareholders equity The company has negative equity. Total equity: -€362k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€104k free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-€362k). Shareholders have been substantially diluted in the past year (over 1502x increase in shares outstanding). Market cap is less than US$10m (€334.4k market cap, or US$353.4k). 공시 • Feb 07
Europlasma S.A. announced that it has received €1.5 million in funding Europlasma S.A. announced a private placement of common shares for the gross proceeds of €1.5 million in a round of funding on February 6, 2023. The company issued common shares in the transaction. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). CEO & Chairman Jérôme Garnache-Creuillot was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Oct 26
First half 2022 earnings released: €0.012 loss per share (vs €0.68 loss in 1H 2021) First half 2022 results: €0.012 loss per share (improved from €0.68 loss in 1H 2021). Revenue: €7.78m (up 92% from 1H 2021). Net loss: €2.44m (loss narrowed 78% from 1H 2021). Reported Earnings • May 01
Full year 2021 earnings released: €0.42 loss per share (vs €0.95 loss in FY 2020) Full year 2021 results: €0.42 loss per share. Revenue: €11.8m (up 80% from FY 2020). Net loss: €12.7m (loss widened 28% from FY 2020). Board Change • Apr 27
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Laurent Collet-Billon is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Reported Earnings • Nov 02
First half 2021 earnings released The company reported a poor first half result with increased losses, weaker revenues and weaker control over costs. First half 2021 results: Revenue: €3.02m (down 3.8% from 1H 2020). Net loss: €11.1m (loss widened 2.4% from 1H 2020). Reported Earnings • Apr 25
Full year 2020 earnings released The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €3.80m (up 15% from FY 2019). Net loss: €9.88m (loss narrowed 6.9% from FY 2019). Is New 90 Day High Low • Feb 24
New 90-day low: €1.58 The company is down 33% from its price of €2.38 on 26 November 2020. The French market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 28
New 90-day low: €1.74 The company is down 25% from its price of €2.31 on 30 October 2020. The French market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 31% over the same period. Reported Earnings • Oct 16
First half earnings released Over the last 12 months the company has reported total losses of €8.89m, with losses narrowing by 84% from the prior year. Reported Earnings • Oct 14
First half earnings released Over the last 12 months the company has reported total losses of €8.89m, with losses narrowing by 84% from the prior year. Is New 90 Day High Low • Oct 14
New 90-day low: €2.64 The company is down 4.0% from its price of €2.75 on 16 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 3.0% over the same period.